Anna Regalia
Research Subjects
Research Interests
Anna Regalia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anna De Amici1 shared publication
- Anna Maria Pisacreta
Department of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Policlinico, 20122 Milan, Italy
1 shared publication - Carlo Alfieri
Department of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico , Milan
1 shared publication - Chiara De Liso1 shared publication
- Emilietta Brigati1 shared publication
Giuseppe Castellano
1 shared publication
Latest Publications
- Open Access
- 13 January 2026
- Published by Aboutscience Srl in Giornale di Clinica Nefrologica e Dialisi
- Vol. 38 (1) , 100-106
From iron to HIF-PH inhibitors: rethinking anemia management after kidney transplant
Anemia is one of the most common complications in patients undergoing kidney transplantation, with an estimated prevalence between 30% and 50%, especially in the first six months after transplantation. The pathogenesis of anemia in these patients is multifactorial, related to chronic inflammation, disorders of iron metabolism, myelosuppression from several immunosuppressive drugs, and hormonal and metabolic alterations. The clinical implications of anemia in kidney transplants are significant: it is a negative prognostic factor for patient and transplant survival, significantly affecting cardiovascular risk and quality of life. This review analyzes in detail the pathogenic mechanisms of anemia in the post-transplant context, illustrating their clinical impact and providing an updated overview of currently available therapeutic strategies, with a focus on new molecules belonging to the class of prolyl-hydroxylase inhibitors (HIF-PHi), which are revolutionizing the therapeutic approach to anemia secondary to renal failure.
- 13 January 2026
- Published by Aboutscience Srl in Giornale di Clinica Nefrologica e Dialisi
- Vol. 38 (1) , 100-106
Open AccessFrom iron to HIF-PH inhibitors: rethinking anemia management after kidney transplant
Anemia is one of the most common complications in patients undergoing kidney transplantation, with an estimated prevalence between 30% and 50%, especially in the first six months after transplantation. The pathogenesis of anemia in these patients is multifactorial, related to chronic inflammation, disorders of iron metabolism, myelosuppression from several immunosuppressive drugs, and hormonal and metabolic alterations. The clinical implications of anemia in kidney transplants are significant: it is a negative prognostic factor for patient and transplant survival, significantly affecting cardiovascular risk and quality of life. This review analyzes in detail the pathogenic mechanisms of anemia in the post-transplant context, illustrating their clinical impact and providing an updated overview of currently available therapeutic strategies, with a focus on new molecules belonging to the class of prolyl-hydroxylase inhibitors (HIF-PHi), which are revolutionizing the therapeutic approach to anemia secondary to renal failure.